Free Trial

Madrigal Pharmaceuticals (MDGL) Competitors

Madrigal Pharmaceuticals logo
$440.36 -2.98 (-0.67%)
As of 11:20 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDGL vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, IONS, HALO, and RGEN

Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.

Madrigal Pharmaceuticals vs. Its Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.68B2.08$1.63B$10.4613.10
Madrigal Pharmaceuticals$180.13M54.33-$465.89M-$12.85-34.31

In the previous week, Biogen had 28 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 31 mentions for Biogen and 3 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.66 beat Madrigal Pharmaceuticals' score of 0.58 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
10 Very Positive mention(s)
8 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Madrigal Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has a net margin of 15.31% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Biogen's return on equity of 13.85% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen15.31% 13.85% 8.32%
Madrigal Pharmaceuticals -54.68%-38.38%-27.32%

Biogen presently has a consensus price target of $181.65, indicating a potential upside of 32.59%. Madrigal Pharmaceuticals has a consensus price target of $483.38, indicating a potential upside of 9.65%. Given Biogen's higher possible upside, equities analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
21 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.32
Madrigal Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Biogen has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500.

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDGL vs. The Competition

MetricMadrigal PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.80B$2.54B$5.72B$10.40B
Dividend YieldN/A53.63%5.53%4.58%
P/E Ratio-34.3723.6076.4326.62
Price / Sales54.33521.29472.7192.34
Price / CashN/A171.0137.4661.85
Price / Book12.745.3713.276.45
Net Income-$465.89M$32.95M$3.29B$271.39M
7 Day Performance5.61%4.01%2.60%3.06%
1 Month Performance6.31%5.96%4.65%7.62%
1 Year Performance97.62%1.93%74.34%30.20%

Madrigal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDGL
Madrigal Pharmaceuticals
3.901 of 5 stars
$440.36
-0.7%
$483.38
+9.8%
+96.4%$9.78B$180.13M-34.2790
BIIB
Biogen
4.6526 of 5 stars
$143.32
-1.1%
$181.65
+26.7%
-28.9%$21.24B$9.68B13.707,605Trending News
Analyst Forecast
UTHR
United Therapeutics
4.5242 of 5 stars
$403.11
-0.5%
$438.85
+8.9%
+22.1%$18.27B$2.88B15.731,305Insider Trade
INCY
Incyte
4.7613 of 5 stars
$83.14
+0.0%
$82.53
-0.7%
+31.8%$16.23B$4.24B18.902,617Analyst Forecast
NBIX
Neurocrine Biosciences
4.4463 of 5 stars
$140.44
-1.0%
$160.00
+13.9%
+24.3%$14.07B$2.36B41.551,800Positive News
Analyst Forecast
EXEL
Exelixis
4.6648 of 5 stars
$39.01
-0.4%
$44.06
+12.9%
+51.0%$10.54B$2.17B18.751,147Positive News
BMRN
BioMarin Pharmaceutical
4.9638 of 5 stars
$53.14
-1.8%
$92.04
+73.2%
-22.7%$10.39B$2.85B15.773,040Positive News
EXAS
Exact Sciences
4.7818 of 5 stars
$53.43
-0.9%
$68.05
+27.4%
-24.7%$10.21B$2.76B-9.847,000Positive News
IONS
Ionis Pharmaceuticals
3.9851 of 5 stars
$61.10
-3.3%
$67.88
+11.1%
+49.6%$10.07B$705M-33.211,069Trending News
Analyst Forecast
HALO
Halozyme Therapeutics
4.5572 of 5 stars
$76.33
-0.7%
$67.11
-12.1%
+32.5%$8.99B$1.02B17.47390Positive News
Analyst Forecast
Insider Trade
RGEN
Repligen
4.8802 of 5 stars
$113.74
+0.2%
$166.67
+46.5%
-11.7%$6.39B$634.44M-454.941,778Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:MDGL) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners